ZURICH, Feb 10 (Reuters) - Patients with a deadly lung disease who took Novartis's (NOVN.VX) Onbrez Breezhaler as well as Pfizer's (PFE.N) Spiriva HandiHaler had better lung function than those taking only the Pfizer treatment, studies showed.